Cemtrex (CETX) Stock Forecast & Price Prediction 2026 | CETX Buy or Sell
In this video, we break down CETX stock today (~$2.10 as of late December 2025), full CETX stock analysis with technical analysis, latest Cemtrex stock news (FY25 revenue $76.5M +14% YoY Dec 29 report, return to operating profit $0.5M, two acquisitions pending close near-term, $2M offering Dec 30), CETX stock price prediction for 2026 (analysts limited, speculative targets $11–$13 average from older data, upside on M&A execution), and buy or sell CETX stock verdict.
Cemtrex Inc (NASDAQ: CETX) operates in security technology (Vicon) and industrial services, pivoting to aerospace/defense via acquisitions (Invocon LOI). FY25: Revenue growth, profitability return, but dilution from offerings, micro-cap volatility.
We cover:
FY25 results & acquisitions: Revenue $76.5M, operating profit turnaround
CETX chart analysis: Volatile downtrend, support ~$2.00–$2.10, resistance $2.50–$3
M&A pipeline: Two deals to boost scale/margins
Risks: Dilution, low liquidity
Buy or sell CETX? Speculative micro-cap turnaround vs execution challenges
Timestamps:
0:00 – CETX Stock Price Today & Overview
2:30 – FY25 Earnings + Profit Return
6:10 – Acquisitions & Offerings
9:50 – CETX Technical Analysis: Levels
13:20 – CETX Stock Forecast 2026 + Targets
16:40 – Buy or Sell CETX? Bull vs Bear
High-risk small cap / tech/industrial play – perfect for day trading, swing trading on news.
Not financial advice – DYOR!
cetx stock,cetx stock analysis,cetx stock review,$cetx stock video,$cetx stock alert,cetx stock alert,$cetx stock,cetx stock news,cetx stock forecast,cetx stocktwits,cetx stock talk,cetx stock price prediction,cetx stock latest news,cetx,stock market,omeros corporation,stocks,sell $cetx,cetx price,cetx trading,cetx volume,cetx analysis,sell cetx,buy cetx,$cetx,stock picks,omeros,stock trading,omeros stock,cetx stonk,stock cetx,cetx news,cetx day trading,cetx market news,stock,stock charts,cetx stock prediction,$cetx volume,about $cetx,$cetx price,omeros stock analysis,zaltenibart,day trade,long term investing,best stocks to buy now,masp-3,latest cetx news,rare disease drug,cetx recent news,stock markethealth care stocks,day trade $cetx,what stocks to buy now,stock analysis,trending stocks,cetx earnings,licensing deal,masp-3 inhibitor,biotech investing,nasdaq cetx,trade cetx,biotech stock,buy $cetxtickerdd,about cetx,novo nordisk,biotech stocks,buy $cetx,cetx nasdaq,#shorts,#daytrading,cetx.o,oms906,investors,stocks to buy,investing,top stocks,swing trading,day trading,technical analysis,stocks to buy now,asset purchase agreement,what stocks to buy,omeros corporation reddit,peak revenue $300m,next upmove here,cetx net loss,long term hold,stocks for beginners,small cap biotech,biotech stock analysis,seres therapeutics stock,why did cetx,live day trade,omeros corporation stock twits,lectin pathway inhibitor,long term upside,omeros novo nordisk deal,novo nordisk deal,dono trade stock,omeros corporation price,day trading live,omeros corporation forecast,omeros earnings call,omeros corporation target,top penny stocks,$cetx omeros corporation,stocks to buy today,cetx earnings call,live day trading,conference call webcast,$2.1 billion deal,novo nordisk partnership,cetx price target,how to day trade,novo nordisk omeros deal,omeros corporation latest news,omeros earnings call transcript,omeros corporation price prediction,small cap stocks,cetx financial results,omeros corporation price target,best day trading stocks,swing trading stocks,stock chat room,omeros corporation news,swing trade cetx,analyst ratings moderate buy,clinical trial phase 3,unity biotechnology stock,omeros corporation buy or sell,omeros corporation price forecast,80% stock jump,omeros corporation after hours,day trade live,omeros corporation stock,rare disease biotech,when to buy stocks,finance,biotechnology,nasdaq,omeros corp,stock jump,rare disease,stock news,stock forecast,pnh drug,zaltenibart oms906,dono trad,biopharma investing,biotech trading,earnings analysis,stock soared,live thinkorswim,cetx predictions,united states,marketbeat cetx,clinical-stage drug,momentum stocks,pnh stock,breakout stock,ubx stock,live daytrade,massive stocks,news cetx,stock surge,viral stock,mcrb stock,$2.1b deal,live stock,pharma m&a,hot stocks,penny stock,stock price,nasdaq biotech,biotech analysis,yartemlea approval,volume spike,biotech rally,breakout momentum,100% gain,cetx earnings,healthcare stocks,$2.1b partnership,first-in-class drug,breakout plays,$1b valuation,clinical trials,swing trade,nvo stock
Информация по комментариям в разработке